Scancell (SCLP) Shares Up 6.6%

Scancell Holdings Plc (LON:SCLP) traded up 6.6% during trading on Wednesday . The stock traded as high as GBX 6.72 ($0.09) and last traded at GBX 6.72 ($0.09). 452,316 shares traded hands during trading, a decline of 16% from the average session volume of 536,966 shares. The stock had previously closed at GBX 6.30 ($0.08).

TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at

About Scancell (LON:SCLP)

Scancell Holdings plc engages in the discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer in the United Kingdom. The company's products include SCIB1, a plasmid DNA vaccine, which is in Phase I/II clinical trials for the treatment of melanoma; SCIB2 to treat lung cancer antigen; and Modi-1, which is in the pre-clinical development to treat triple negative breast cancer, ovarian cancer, and sarcoma.

Recommended Story: What is Cost of Capital?

Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit